Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed squamous cell carcinoma of the head and neck incurable by surgery or radiation
Patients must have measurable disease, defined as at least on e lesion that can be accurately measured in the one dimension (longer diameter to be recorded) as greater then or equal to 20mm with conventional techniques or as greater than or equal to 10mm with computed tomograpy (CT) scan.
Therapeutic history that includes the Following:
No prior EGFR-based therapy for recurrent disease
No chemotherapy or irradiation with the 28-day period preceding entry to the study
Eastern Cooperative Oncology Group (ECOG)performance Status 0-2 (kamofsky \>59%)
Patients must have normal organ and marrow function as defined below:
leukocytes \>3,000ml
absolute neutrophil count 1,500/ml
platelets 100,000/ml
total bilirubin within normal institutional limits
AST(SGOT)ALT(SGPT) \<2.5 X institutional upper limits of normal
Creatinine \<1.5
You may not be if
Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical in situ.
Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, ketoconazole, erythromycin, clarithromycin, atorvastatin, cimetidine, ametidine, amitriptyline, imipramine, verpamil, tamoxifen, chlorpromazine, amiodorone, chloroquine, St. John's Wort
Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy
Incomplete healing from previous oncologic or other major surgery Patients may not be receiving any other investigational agents
History of allergic reactions attributed to compound of similar chemical or biologic composition to ZD 1839
Uncontrolled intercurrent illness
Pregnancy or breast feeding (women of child -bearing potential
Clareo Health | A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
